Remdesivir (Veklury) in High-Risk Outpatients with COVID-19

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2022年 / 64卷 / 1644期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：31 / 32
页数：2
相关论文
共 50 条
  • [1] Remdesivir (Veklury) for COVID-19
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1612): : 186 - 188
  • [2] Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients
    Odeti, Shyam
    Yellepeddi, Venkata K.
    [J]. AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 311 - 312
  • [3] Early Convalescent Plasma for High-Risk Outpatients with Covid-19
    Korley, Frederick K.
    Durkalski-Mauldin, Valerie
    Yeatts, Sharon D.
    Schulman, Kevin
    Davenport, Robertson D.
    Dumont, Larry J.
    El Kassar, Nahed
    Foster, Lydia D.
    Hah, Jennifer M.
    Jaiswal, Siddartha
    Kaplan, Alesia
    Lowell, Ezekiel
    McDyer, John F.
    Quinn, James
    Triulzi, Darrell J.
    Van Huysen, Carol
    Stevenson, Valerie L. W.
    Yadav, Kabir
    Jones, Christopher W.
    Kea, Bory
    Burnett, Aaron
    Reynolds, Joshua C.
    Greineder, Colin F.
    Haas, Nathan L.
    Beiser, David G.
    Silbergleit, Robert
    Barsan, William
    Callaway, Clifton W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21): : 1951 - 1960
  • [4] In high-risk outpatients with COVID-19, remdesivir reduced COVID-19-related hospitalization or all-cause death at 28 d
    Mourad, Omar
    Chagla, Zain
    [J]. ANNALS OF INTERNAL MEDICINE, 2022, 175 (05) : JC50 - JC50
  • [5] Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
    Gottlieb, R. L.
    Vaca, C. E.
    Paredes, R.
    Mera, J.
    Webb, B. J.
    Perez, G.
    Oguchi, G.
    Ryan, P.
    Nielsen, B. U.
    Brown, M.
    Hidalgo, A.
    Sachdeva, Y.
    Mittal, S.
    Osiyemi, O.
    Skarbinski, J.
    Juneja, K.
    Hyland, R. H.
    Osinusi, A.
    Chen, S.
    Camus, G.
    Abdelghany, M.
    Davies, S.
    Behenna-Renton, N.
    Duff, F.
    Marty, F. M.
    Katz, M. J.
    Ginde, A. A.
    Brown, S. M.
    Schiffer, J. T.
    Hill, J. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04): : 305 - 315
  • [6] Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19
    Fox, Matthew P.
    D'Agostino McGowan, Lucy
    James, Bryan D.
    Lessler, Justin
    Mehta, Shruti H.
    Murray, Eleanor J.
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2021, 190 (04) : 491 - 495
  • [7] Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
    Dryden-Peterson, Scott
    Kim, Andy
    Joyce, Mary-Ruth
    Johnson, Jennifer A.
    Kim, Arthur Y.
    Baden, Lindsey R.
    Woolley, Ann E.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (11):
  • [8] Remdesivir (VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In Vivo Cardiac Electrophysiological Effects
    Pilote, Sylvie
    Simard, Chantale
    Drolet, Benoit
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 80 (04) : 616 - 622
  • [9] Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19
    Bruno, Giuseppe
    Giotta, Massimo
    Perelli, Serena
    De Vita, Giuseppina
    Bartolomeo, Nicola
    Buccoliero, Giovanni Battista
    [J]. VIRUSES-BASEL, 2022, 14 (11):
  • [10] Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan
    Mizuno, Takahito
    Kondo, Yu
    Sakai, Mikiyasu
    Saneyasu, Kenichi
    Kojima, Ryota
    Miyake, Yoshio
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2024, 30 (08) : 716 - 724
12345